mNSCLC with both PD-L1 and an Actionable Mutation

(2:13)

Treating ALK+ mNSCLC With ALK Inhibitors

(4:58)

MET Exon 14 Mutations in mNSCLC

(13:6)

Immunotherapy Treatments for Non-Small Cell Lung Cancer (NSCLC)

(3:30)

KEYNOTE-189: Chemotherapy and Pembrolizumab in mNSCLC

(5:42)

Case Overview: A 57-Year-Old Man With ALK+ mNSCLC

(2:5)

LUNAR: Tumor Treating Field (TTFields) therapy with SOC in mNSCLC following platinum failure

(5:21)

Understanding Non-Small Cell Lung Cancer

(4:44)

Treatment Options for mNSCLC After Progression

(5:16)

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC

(3:48)

KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC

(4:48)

Restorative microbiota therapy with chemo-immunotherapy in NSCLC

(55)

HARMONi-02 Comparing Ivonescimab vs. Pembrolizumab in Patients with mNSCLC

(5:19)

Targeted Therapies for BRAF V600E-Mutated mNSCLC

(3:53)

Current Status of Adjuvant Therapy for NSCLC

(23:42)

2023 Best of Lung: Targeted Therapies in Lung Cancer

(30:32)

Expert Cancer Panel: mNSCLC, ALK+, w/ CNS progression and controlled systemic disease on alectinib

(18:52)

What is the role of radiotherapy in treating NSCLC with brain metastases?

(38)

Therapeutic Algorithm for NSCLC Adenocarcinoma

(26:13)

Understanding Biomarker Testing in Non-Small Cell Lung Cancer

(6:14)